Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.

CONCLUSIONS: Evidence concerning the efficacy and safety of glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients is limited. Existing studies examine more intensive versus less intensive insulin therapy, and the use of DPP4 inhibitors and pioglitazone. The safety and efficacy of more intensive compared to less intensive insulin therapy is very uncertain and the safety and efficacy of DPP4 inhibitors and pioglitazone is uncertain, due to data being limited and of poor quality. Additional RCTs are required to clarify the safety and efficacy of current glucose-lowering agents for kidney transplant recipients with diabetes.
PMID: 28238223 [PubMed - as supplied by publisher]

Source: Cochrane Database of Systematic Reviews - February 26, 2017 Category: Journals (General) Authors: Lo C, Jun M, Badve SV, Pilmore H, White SL, Hawley C, Cass A, Perkovic V, Zoungas S Tags: Cochrane Database Syst Rev Source Type: research